1XT Stock Chart & Stats
€0.01
€0.00(0.00%)
At close: 4:00 PM EST
€0.01
€0.00(0.00%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.05
Previous CloseN/A
Volume0.00
Average Volume (3M)1.09K
Market Cap
€12.30M
Enterprise Value€172.39
Total Cash (Recent Filing)€30.72M
Total Debt (Recent Filing)€30.00M
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Nov 27, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding861,266,850
10 Day Avg. Volume3,257
30 Day Avg. Volume1,089
Financial Highlights & Ratios
PEG Ratio-1.38
Price to Book (P/B)-37.15
Price to Sales (P/S)85.84
P/FCF Ratio-4.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)€1.01M
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetZero recent debt reduces refinancing and interest-related pressure, giving the company some financial flexibility while it develops its pipeline. This is a meaningful balance-sheet advantage versus leveraged peers, although it does not offset the negative-equity position.
ITGA10 Platform BreadthAn ITGA10-centered platform spans regenerative medicine and oncology, giving Xintela multiple potential development paths from one biological target. That breadth can support partnering, target validation and future licensing opportunities if the programs achieve clinical and commercial progress.
Positive Gross ProfitPositive gross profit in 2024–2025 indicates that some reported activity generated value above direct costs, a better base than a business with persistently negative gross profit. However, the evidence supports only an early foundation, not proven profitability or durable scale.
Bears Say
Negative Shareholders’ EquityNegative shareholders’ equity materially weakens balance-sheet resilience and limits financial flexibility, even without debt. It can make the company more dependent on external capital to support development, increasing funding sensitivity while the pipeline remains commercially unproven.
Persistent Cash BurnSustained operating cash burn shows that current activities do not fund themselves and that cash generation is not yet supporting the cost structure. Continued development therefore depends on external financing, which can constrain execution and create recurring funding pressure.
Weak Commercial TractionSmall, volatile revenue and a year-over-year decline indicate limited commercialization traction relative to the cost base. Persistent EBIT and net losses suggest that current activities have not yet produced a durable earnings engine, leaving value dependent on future pipeline progress.
Xintela AB News
1XT FAQ
What was Xintela AB’s price range in the past 12 months?
Xintela AB lowest stock price was <€0.01 and its highest was €0.05 in the past 12 months.
What is Xintela AB’s market cap?
Xintela AB’s market cap is €12.30M.
When is Xintela AB’s upcoming earnings report date?
Xintela AB’s upcoming earnings report date is Nov 27, 2026 which is in 69 days.
How were Xintela AB’s earnings last quarter?
Xintela AB released its earnings results on Aug 28, 2026. The company reported >-€0.001 earnings per share for the quarter.
Is Xintela AB overvalued?
According to Wall Street analysts Xintela AB’s price is currently Overvalued.
Does Xintela AB pay dividends?
Xintela AB does not currently pay dividends.
What is Xintela AB’s EPS estimate?
Xintela AB’s EPS estimate is 0.
How many shares outstanding does Xintela AB have?
Xintela AB has 861,266,850 shares outstanding.
What happened to Xintela AB’s price movement after its last earnings report?
Xintela AB reported an EPS of >-€0.001 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Xintela AB?
Currently, no hedge funds are holding shares in DE:1XT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xintela AB
Xintela AB (publ), a biomedical company established in 2009 in Lund, Sweden, concentrates its efforts on two key areas: regenerative medicine, particularly for cartilage repair, and oncology, with a focus on brain tumors. Central to their work is XINMARK, a patented marker technology used to accurately identify and isolate specific stem cells that can develop into cartilage cells. Their product portfolio includes XSTEM, a stem cell-based therapy undergoing clinical trials for treating knee osteoarthritis and persistent leg ulcers. They also offer EQSTEM, another stem cell product, for managing joint conditions in horses. In oncology, Xintela is engaged in the preclinical development of therapeutic antibodies designed to combat aggressive cancers like glioblastoma, a severe brain tumor, and triple-negative breast cancer.
Technical Analysis
Xbrane Biopharma AB
―
Isofol Medical AB
―
Elicera Therapeutics AB
―
Active Biotech AB
―
NextCell Pharma AB
―